Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Igen

This article was originally published in The Gray Sheet

Executive Summary

Private equity financing raises $9.5 mil. for R&D and working capital. The sale of 789,075 shares to Acqua Wellington North American Equities Fund was made under a February financing agreement covering the sale of up to $60 mil. of Igen's common stock over 28 months. Separately, a pretrial hearing in the biological detection system firm's 1997 breach of contract suit against Roche Diagnostics relating to a 1992 licensing agreement has dismissed Roche's counterclaim for fraud and struck down Roche's request for punitive damages. The U.S. District Court in Maryland has set a trial date of Oct. 23 (1"The Gray Sheet" April 10, 2000, p. 22)

You may also be interested in...



Roche Sees Minimal Elecsys Financial Impact In Wake Of IGEN Court Order

Roche Diagnostics expects only a "small percentage" of its Elecsys line of immunoassay analyzers incorporating IGEN's Origen technology will be affected by an upcoming court-ordered transfer of Elecsys physician office laboratory accounts to IGEN.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

MT014684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel